DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration.
Here at Genentech, we are transforming ophthalmology
… and opening up The Window to Change.
Vision loss affects more than 250 million people worldwide, making it one of the leading public health issues in the world. Currently, visual impairment is expected to reach 43 million patients with DME and 29 million patients with nAMD by 2040. At Genentech, we are focused on tackling these problems from a new perspective. With the global retina community, we are changing how we approach medical innovation by exploring cutting-edge technology and pioneering new therapies. We are changing how patients experience their care, for the better, by looking beyond the therapy, developing integrated digital solutions that support patients and physicians every step of the way. Join us as we lead and help shape the future of ophthalmology, together.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.